- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03649321
Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer
A phase1b/2 Clinical Trial of Chemotherapy and the AXL-inhibitor Bemcentinib for Patients With Metastatic Pancreatic Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75390-9179
- University of Texas Southwestern Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Ability to understand and the willingness to sign a written informed consent.
- Patients must have histologically or cytologically confirmed recurrent or metastatic pancreatic adenocarcinoma.
No prior systemic therapy for metastatic or recurrent disease.
- Prior adjuvant therapy, if completed more than 6 months prior to date of enrollment, is acceptable.
- Radiosensitizing chemotherapy, if completed at least 4 weeks from date of enrollment, is acceptable.
- Measurable disease per RECIST1.1 criteria
- Age 18-70 years at the time of enrollment
- ECOG performance status 0 or 1
- Have resolution of toxic effect(s) or intervention complication to Grade 1 or less (except alopecia) from any prior chemotherapy, major surgery, or radiation therapy of >30 Gy.
Adequate hematologic, hepatic, and renal function. All screening labs should be performed within 14 days of enrollment date.
- Hemoglobin ≥ 10 g/dL
- ANC ≥ 1,500/µL
- Platelets ≥ 100,000/µL
- Total bilirubin < 1.5 x institutional ULN
- AST (SGOT) & ALT(SGPT)≤ 2.5 x institutional ULN in patients without known liver metastasis; ≤ 5 x institutional ULN in patients with known liver metastasis
- Serum creatinine ≤ 1.5 times ULN, and calculated creatinine clearance ≥ 60 mL/min using the Cockcroft-Gault equation)
- INR or PT International Normalized Ratio (INR) or Prothrombin Time (PT) ≤1.5 times the ULN
- Albumin ≥ 3.0 g/dL
Female patients of childbearing potential must have a negative pregnancy test (either urine or serum pregnancy test). If the urine pregnancy test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
- Has not undergone a hysterectomy or bilateral oophorectomy; or
- Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 120 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician, or study team member, immediately.
Exclusion Criteria:
- Is currently participating and receiving study therapy in a first line setting for metastatic or recurrent pancreatic adenocarcinoma.
- Participated in a study of an investigational agent or used an investigational device within 4 weeks of the first dose of study treatment.
- Patients with known untreated brain metastases. Patients without known or suspected brain metastases do not require radiologic imaging prior to enrollment.
- Has a known additional malignancy that is progressing or requires active treatment. Note: Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, significant pulmonary disease (shortness of breath at rest or mild exertion), or uncontrolled infection or psychiatric illness/social situations that would limit compliance with study requirements.
- History of the following cardiac conditions:
- Congestive cardiac failure of >Grade II severity according to the NYHA (defined as symptomatic at less than ordinary levels of activity);
- Ischemic cardiac event including myocardial infarction within 3 months prior to date of enrollment
- Uncontrolled cardiac disease, including unstable angina pectoris, uncontrolled hypertension (i.e. sustained systolic BP >160 mmHg or diastolic BP >90 mmHg), cardiac arrhythmia, or need to change medication due to lack of disease control within 6 weeks prior to date of enrollment;
- History or presence of sustained bradycardia (≤55 BPM), left bundle branch block, cardiac pacemaker or ventricular arrhythmia. Note: Patients with a supraventricular arrhythmia requiring medical treatment, but with a normal ventricular rate are eligible;
- Known family history or personal history of long QTc syndrome or previous drug-induced QTc prolongation of at least Grade 3 (QTc >500 ms).
- Abnormal left ventricular ejection fraction (LVEF) on ECHO or MUGA less than <45%.
- Current treatment with any agent known to cause Torsades de Pointes which cannot be discontinued at least five half-lives or two weeks prior to the first dose of study treatment.
- Screening 12-lead ECG, in triplicate, with a measurable QTc interval according to Fridericia's correction >450 ms.
- Known active infection with human immunodeficiency virus (HIV), hepatitis B or C viruses (screening not required, follow institutional practice):
- Patients who have a history of hepatitis B infection are eligible provided they are hepatitis B surface antigen negative.
- Patients who have a history of hepatitis C infection are eligible provided they have no evidence of hepatitis C ribonucleic acid using a quantitative polymerase chain reaction assay at least 6 months after completing treatment for hepatitis C infection.
- Active, clinically significant serious infection requiring treatment with antibiotics, anti-virals or anti-fungals.
- Treatment with any medication which is predominantly metabolized by CYP3A4 and has a narrow therapeutic index
- Major surgery within 4 weeks prior to date of enrollment; excluding skin biopsies and procedures for insertion of central venous access devices.
- Inability to tolerate oral medication
- Existing gastrointestinal disease affecting drug absorption such as celiac disease or Crohn's disease, or previous bowel resection which is considered to be clinically significant or could interfere with absorption.
- Known lactose intolerance
- Is pregnant or breastfeeding
- Any significant medical condition lab abnormality, or psychiatric illness, in the opinion of the investigator, that might interfere with the patient's participation in the study or in the evaluation of the study results.
- Unwillingness or inability to comply with study procedures.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase 1b
bemcentinib 200 mg oral daily every 21 days.
Nab-paclitaxel 100 mg/m^2 Day 1 /8 every 21 days.
Gemcitabine 800 mg/m^2 Day 1 /8 every 21 days.
Cisplatin 25 mg/m^2 Day 1 /8 every 21 days.
|
200mg orally starting Cycle 1 day 2 every 21 days or 28 days.
25 mg/m^2 Day 1 /8 every 21 days or 28 days.
Other Names:
Gemcitabine 1000 mg/m^2 Day 1 /8 every 21 days or 28 days
Other Names:
Cisplatin 25 mg/m^2 Day 1 /8 every 21 days
|
Experimental: Phase 2
bemcentinib 200 mg oral daily every 28 days.
Nab-paclitaxel 125 mg/m^2 Day 1 /8 /15 every 28 days.
Gemcitabine 1000 mg/m^2 Day 1 /8 /15 every 28 days.
|
200mg orally starting Cycle 1 day 2 every 21 days or 28 days.
25 mg/m^2 Day 1 /8 every 21 days or 28 days.
Other Names:
Gemcitabine 1000 mg/m^2 Day 1 /8 every 21 days or 28 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (ORR)
Time Frame: Every 4 months from time of first dose of study drug until completion of treatment for approximately 42 months.
|
Determine the clinical activity as defined by overall response rate (ORR) of bemcentinib plus chemotherapy (nab-paclitaxel/gemcitabine) in patients with metastatic pancreatic adenocarcinoma.
The analyses of ORR was performed on the Response Evaluable Population.
ORR is defined as the proportion of patients with CR+partial response as their best clinical response.
|
Every 4 months from time of first dose of study drug until completion of treatment for approximately 42 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete Response Rate (CR)
Time Frame: Every 4 months from time of first dose of study drug until completion of treatment for approximately 42 months.
|
Determine clinical activity of bemcentinib plus chemotherapy as defined by complete response rate (CRR), partial response, stable disease, duration of response - overall response/stable disease, median progression free survival (PFS) and overall survival (OS) rate.
|
Every 4 months from time of first dose of study drug until completion of treatment for approximately 42 months.
|
Clinical Benefit Rate
Time Frame: Every 4 months from time of first dose of study drug until completion of treatment for approximately 42 months.
|
Determine clinical benefit rate as defined by complete response (CR), Partial Response (PR), and Stable Disease (SD) response rates.
Clinical benefit response - percent of CR, PR, and SD.
|
Every 4 months from time of first dose of study drug until completion of treatment for approximately 42 months.
|
Number of Participants With an Adverse Event of Grade 3 or Higher
Time Frame: Every 4 months from time of first dose of study drug until completion of treatment for approximately 42 months.
|
Assess safety and tolerability of bemcentinib plus chemotherapy in patients with metastatic pancreatic adenocarcinoma and will be graded according to the NCI CTCAE, Version 5
|
Every 4 months from time of first dose of study drug until completion of treatment for approximately 42 months.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Syed Kazmi, MD, University of Texas Southwestern Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Pancreatic Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Paclitaxel
- Albumin-Bound Paclitaxel
- Gemcitabine
Other Study ID Numbers
- STU 062018-024
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer of Pancreas
-
Washington University School of MedicineCompletedPancreatic Cancer | Pancreas Cancer | Pancreas Neoplasms | Cancer of Pancreas | Cancer of the PancreasUnited States
-
Joseph J. CullenNational Cancer Institute (NCI); National Institutes of Health (NIH); Holden... and other collaboratorsActive, not recruitingAdenocarcinoma | Pancreatic Neoplasms | Pancreas Cancer | Pancreas Neoplasms | Cancer of Pancreas | Cancer of the Pancreas | Neoplasms, PancreaticUnited States
-
Emory UniversityCompletedPancreas Cancer | Pancreas Neoplasms | Cancer of Pancreas | Cancer of the Pancreas | Neoplasms, PancreaticUnited States
-
Washington University School of MedicineNational Cancer Institute (NCI); BioMed Valley Discoveries, IncTerminatedPancreatic Cancer | Pancreas Cancer | Cancer of Pancreas | Cancer of the PancreasUnited States
-
National Cancer Institute (NCI)CompletedPancreatic Neoplasms | Pancreatic Cancer | Pancreas Cancer | Cancer of Pancreas | Cancer of the PancreasUnited States
-
BioXcel Therapeutics IncIQVIA BiotechWithdrawnPancreatic Cancer | Pancreas Cancer | Cancer of Pancreas | Cancer of the Pancreas | Neoplasms, PancreaticUnited States
-
AmgenTerminatedPancreatic Cancer | Pancreas Cancer | Cancer of Pancreas | Cancer of the Pancreas
-
Washington University School of MedicineTerminatedPancreatic Cancer | Pancreas Cancer | Cancer of Pancreas | Cancer of the PancreasUnited States
-
NantCell, Inc.TakedaTerminatedCancer | Pancreatic Cancer | Advanced Solid Tumors | Metastatic Cancer | Bone Metastases | Solid Tumors | Pancreas Cancer | Adenocarcinoma of the Pancreas | Oncology | Cancer of Pancreas | Metastatic Pancreatic Cancer | Metastases | Cancer of the Pancreas | Advanced Malignancy | Oncology Patients | Endocrine CancerItaly, Spain, United Kingdom, Belgium, Canada, Denmark, Romania, United States, Germany, Netherlands, Korea, Republic of, Russian Federation, Australia, Austria, Lithuania, Portugal, Greece, Poland, Switzerland, Serbia, Bulgaria, ... and more
-
Dartmouth-Hitchcock Medical CenterCompletedInjury of Body of PancreasUnited States
Clinical Trials on Bemcentinib
-
BerGenBio ASACompletedCOVID-19India, South Africa
-
GWT-TUD GmbHAmsterdam UMC, location VUmc; BerGenBio ASA; Groupe Francophone des MyelodysplasiesCompletedAcute Myeloid Leukemia | High-risk Myelodysplastic Syndrome | Low-risk Myelodysplastic SyndromeGermany, Netherlands, France
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI); BerGenBio ASATerminatedBrain and Central Nervous System TumorsUnited States
-
BerGenBio ASAMerck Sharp & Dohme LLCTerminatedTriple Negative Breast Cancer | Inflammatory Breast Cancer Stage IVSpain, United States, United Kingdom, Norway
-
BerGenBio ASACompletedNon-Small Cell Lung CancerUnited States
-
BerGenBio ASAMerck Sharp & Dohme LLCCompletedLung Cancer Metastatic | Adenocarcinoma of Lung | NSCLC Stage IVUnited States, Spain, United Kingdom, Norway
-
BerGenBio ASARecruiting
-
BerGenBio ASAActive, not recruitingAcute Myeloid Leukemia | Myelodysplastic SyndromesUnited States, Germany, Italy, Norway
-
University of LeicesterEli Lilly and Company; GlaxoSmithKline; Merck Sharp & Dohme LLC; Roche Pharma AG; British Lung Foundation and other collaboratorsActive, not recruitingMesothelioma, MalignantUnited Kingdom